Milestone Pharmaceuticals, Inc. (MIST) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.91

From 52W high−68.96%

Volume562357.00

Market cap$114.02M

P/E (TTM)—

P/S (TTM)48.7x

Div yield—

Key dataSep 18, 2026

Open

$0.91

From 52W high

−68.96%

Volume

562357.00

Market cap

$114.02M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.2x

P/E (TTM)

—

RSI (14)

32.7

MomentumView details →

1D Return

−0.41%

YTD Return

−54.75%

SummaryUpdated Jun 1, 2026

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is a Canadian biopharmaceutical company founded in 2003 and headquartered in Montréal. The company went public in May 2019 and focuses exclusively on developing cardiovascular medicines for patients with heart rhythm disorders. Milestone is currently a clinical-stage company with no approved products on the market, dedicating its resources to advancing its lead drug candidate etripamil through late-stage clinical trials for treating specific types of rapid heart rhythm conditions.

Ask drillr about Milestone Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.2x

EV/Sales

36.4x

P/S (TTM)

48.7x

P/B (TTM)

6.3x

ProfitabilityView details →

Gross Margin

94.58%

Net Margin

−3585.62%

EBITDA Margin

−3124.58%

ROE (TTM)

−461.14%

ROA (TTM)

−46.26%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

—

EPS YoY

+18.82%

FCF YoY

−51.44%

Revenue CAGR 3Y

−32.38%

EPS CAGR 3Y

−11.94%

EBITDA YoY

−42.88%

MomentumView details →

1D Return

−0.41%

YTD Return

−54.75%

1Y Return

−52.40%

RSI (14)

32.7

vs 50D SMA

−19.07%

vs 200D SMA

−42.73%

Capital & dividendView details →

Debt/Equity

7.79x

Current Ratio

8.13x

Quick Ratio

7.92x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.21

EPS Surprise

−7.69%

Beats (12Q)

7/12

Next Q EPS Est

−$0.22

Avg Surprise (4Q)

−100.13%

Rev Surprise

−31.55%

Financials snapshotView financials →

Revenue (TTM)

2.34M

Net Income (TTM)

−84.01M

Op. CF (TTM)

−61.18M

Next earningsNov 11, 2026 →

Latest newsMore news →

Milestone Pharmaceuticals initiated the pivotal Phase 3 ReVeRA-301 trial of its etripamil nasal spray for self-administered treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR).30d ago

Similar companies

Genelux CorporationGNLX Coya Therapeutics, Inc.COYA PMV Pharmaceuticals, Inc.PMVP Tiziana Life Sciences LtdTLSA Black Diamond Therapeutics, Inc.BDTX Vaxart, Inc.VXRT Find similar companies →

Latest newsMore news →

China's National Medical Products Administration approved the launch of Milestone Pharmaceuticals Inc.'s etripamil nasal spray (brand name: Xingbituo) for treating acute episodes of paroxysmal supraventricular tachycardia in adults.17d ago Milestone Pharmaceuticals initiated the pivotal Phase 3 ReVeRA-301 trial of its etripamil nasal spray for self-administered treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR).30d ago